NeoPhore Appoints Pioneering Cancer Researchers and Clinicians to Scientific Advisory Board

Company attracts world-leading researchers who discovered the role of mismatch repair biology in cancer and cancer immunotherapy

8th January 2018, Cambridge, UK – NeoPhore Limited, a cancer immuno-oncology company today announced the formation of its Scientific Advisory Board, featuring internationally-renowned experts in the fields of cancer genetics, translational clinical oncology and immuno-oncology.
The NeoPhore Scientific Advisory Board will be chaired by NeoPhore Scientific Founder Professor Alberto Bardelli, Department of Oncology at the University of Torino, and deputy Director of the Candiolo Cancer Institute-IRCCS, Torino, Italy. In addition to his role in founding NeoPhore, Professor Bardelli also co-founded Horizon Discovery, Plc and he is also the President Elect of the European Association for Cancer Research (EACR). Professor Bardelli’s ground-breaking mechanistic insights into dynamic neoantigen evolution and cancer immunology were recently featured as a research manuscript published in the journal Nature.

Full Press Release

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...